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Abstract
Background: RASSF1A, a tumor suppressor gene, is frequently inactivated in lung cancer leading to a YAP-dependent
epithelial-mesenchymal transition (EMT). Such effects are partly due to the inactivation of the anti-migratory RhoB GTPase
via the inhibitory phosphorylation of GEF-H1, the GDP/GTP exchange factor for RhoB. However, the kinase responsible for
RhoB/GEF-H1 inactivation in RASSF1A-depleted cells remained unknown.
Methods: NDR1/2 inactivation by siRNA or shRNA effects on epithelial-mesenchymal transition, invasion, xenograft
formation and growth in SCID−/− Beige mice, apoptosis, proliferation, cytokinesis, YAP/TAZ activation were investigated
upon RASSF1A loss in human bronchial epithelial cells (HBEC).
Results: We demonstrate here that depletion of the YAP-kinases NDR1/2 reverts migration and metastatic properties
upon RASSF1A loss in HBEC. We show that NDR2 interacts directly with GEF-H1 (which contains the NDR phosphorylation
consensus motif HXRXXS/T), leading to GEF-H1 phosphorylation. We further report that the RASSF1A/NDR2/GEF-H1/
RhoB/YAP axis is involved in proper cytokinesis in human bronchial cells, since chromosome proper segregation are NDR-
dependent upon RASSF1A or GEF-H1 loss in HBEC.
Conclusion: To summarize, our data support a model in which, upon RASSF1A silencing, NDR2 gets activated,
phosphorylates and inactivates GEF-H1, leading to RhoB inactivation. This cascade induced by RASSF1A loss in bronchial
cells is responsible for metastasis properties, YAP activation and cytokinesis defects.
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Background
RASSF1A [Ras association (RalGDS/AF-6) domain fam-
ily member 1], a tumor and metastatic suppressor gene,
is frequently inactivated and an independent predictor of
poor prognosis in resected early-stage non–small cell
lung cancer (NSCLC) [1, 2]. This worse prognosis value
could be sustained by the disturbance of both Rho
GTPases [3, 4], and Hippo signaling pathways [3, 5].
RASSF1A loss in human bronchial epithelial cells
(HBEC), actually leads to the inactivation of RhoB [3], a
Rho GTPase with anti-cell migratory properties [6] and the
nuclear translocation of the transcriptional co-activator
YAP, with subsequent epithelial-mesenchymal transition
(EMT) favoring cell migration and invasion [3]. RhoB in-
activation upon RASSF1A loss is the consequence of Rho
guanine nucleotide exchange factor GEF-H1 inactivation by
phosphorylation [3]. The kinase leading to GEF-H1 inacti-
vation in RASSF1A-depleted HBEC remained unanswered.
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The Hippo kinases, NDR1 (STK38) and NDR2
(STK38L) are shown to both phosphorylate/inactivate
YAP, one of the terminal targets of Hippo signaling [7, 8]
and phosphorylate/inactivate rabin8, a GEF for Rab
GTAPses [9]. We thus examined NDR1/2 in the context
of RASSF1A loss and report that NDR1/2 knockdown
reverted metastatic properties and YAP activation caused
by RASSF1A loss in HBEC. We provide evidence for a
NDR2/GEF-H1 interaction, leading to GEF-H1 Ser885
phosphorylation/inactivation, followed by RhoB down-
regulation. Given the involvement of GEF-H1 and NDR
kinases in cell cycle [10, 11], we investigated cell cycle al-
terations in RASSF1A-depleted HBEC. We found that
RASSF1A knockdown induced mitotic abscission defects,
which were reverted upon GEF-H1 overexpression or
NDR1/2 depletion. We propose a model in which, upon
RASSF1A silencing, NDR2 gets activated, phosphorylates
GEF-H1, leading to GEF-H1 inactivation, followed by
RhoB inactivation. Consequently, RhoB inactivation leads
to the cancer-associated phenotypes observed in
RASSF1A-depleted HBEC.
Methods
Cell culture and transfection
A previous procedure was followed [3]. Cells, whose
main molecular alterations are presented Additional file 1:
Table S1, were transfected using Lipofectamine RNAi-
MAX® (Invitrogen™) with siRNA, plasmid DNA or con-
trol mimics (Dharmacon™) (Additional file 1: Table S2).
Non phosphorylatable GEF-H1 mutants (S265A, S885A)
were generated by mutagenesis (Mutagenex, Inc., Suwa-
nee, USA).
ShNDR1 or NDR2 and SCID mice xenograft
The experiments were performed according to the Euro-
pean Convention for the Protection of Vertebrates Used
for Scientific Purposes (Project # 13256).
Groups of ten, strain 250, 6 weeks-old, male Fox Chase
SCID−/− Beige mice from Charles River™ were anaesthe-
tized according to the manufacturer’s recommendations for
xenografting. ShControl (shRNA Control, Sigma-Aldrich
ShNDR1- (NM_007271.2-875s21c1, 5′-CCGGGTATT
AGCCATAGACTCTATTCTCGAGAATAGAGTCTATG
GCTAATACTTTTTG-3′, Sigma-Aldrich) or shNDR2-
(NM_015000.3-1353s21c1, 5′-CCGGGGCTTGCTTG
GCGTAGATAACCTCGAGGTTATCTACGCCAAGCAA
GCCTTTTTG-3′, Sigma-Aldrich) infected A549
(RASSF1A null) or H1299 (RASSF1A null) cells suspension
(1 × 107 cells/0.1ml) were injected sub-cutaneously in the
left flank of each animal. Mice were monitored for tumor
growth thrice a week. Tumors were allowed to grow to
1000mm3 before euthanasia of the mice. The post-mortem
examination included macroscopic description of lungs and
liver as described [3]. Tumor xenografts, lungs and liver
were rapidly removed and fixed in PFA 4% for histo-
logical analysis as described [3].
Reverse transcription-quantitative real-time-PCR (RT-PCR)
After extraction, RT-PCR was done with each primer sets
(Additional file 1: Table S2) as described [3]. RT-PCR data
were normalized to the human S16. Relative quantification
was calculated using the ΔΔCt method.
λ-Phosphatase assay and immunoblotting
Whole cell protein extracts were prepared as previously
[3]. Proteins (2 μg) were incubated with 400 units of
λ-phosphatase (Santa Cruz™) and 2 mM MnCl2 at 30 °C.
After 30 min, λ-phosphatase was inactivated at 95 °C for
5 min. Proteins were detected by immunoblotting with
primary antibody (Additional file 1: Table S3) diluted at
1:1000 in Tween (0.1%)-TBS buffer and HRP-conjugated
secondary antibody and revealed by ECL kit (Promega™).
Immunofluorescence and image analysis
Cells were fixed and permealized as described [3]. Pri-
mary antibodies (Additional file 1: Table S3) were diluted
at 1:100. Secondary antibodies (AlexaFluo, Invitrogen™)
were added for 1 h. Coverslips were mounted with DAPI
(Santa Cruz™), and image captured with high-throughput
confocal microscopy (FluoView FV1000, Olympus™).
Immunohistochemistry
Immunohistochemistry was assayed according standard
procedures. Slides were incubated overnight at 4 °C with
primary antibodies (Additional file 1: Table S3) diluted
at 1:200 then revealed using the Novolink (Leica) kit.
Wound healing assay
Cells grown onto 24-well Collagen IV coated plates (BD
Biocoat™) were treated with mitomycin C (1 μg/ml) 12 h
before an artificial “wound” created at 0 h. Photographs
were taken (X10) at 0 h and 12 h. The distances traveled
were expressed as μm/h.
Migration 3D & invasion assays
Cells (20 × 103) were added in the top invasion chambers
of 24-well transwell plates containing cell culture insert
(BD BioCoat Matrigel® Invasion Chamber, BD Biosci-
ences™). At 48 h, migrating cells were stained with
crystal violet.
Bromodeoxyuridine (BrdU) incorporation analysis
Cells labeled with BrdU (1:500 dilution, cell proliferation
assay, Millipore) for 24 and 48 h were fixed for 30 min
then BrdU was detected using anti-BrdU mouse mono-
clonal antibody followed by peroxidase-conjugated goat
anti-mouse IgG antibody. The colored reaction was
quantified using a microplate reader at 450 nm.
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DNA fragmentation assays
Cells (1 × 105) were resuspended in lysis buffer (200 μL)
supplied by the manufacturer (Cell Death Detection;
Roche). The cytoplasmic fraction (20 μL) was used for
the enzyme-linked immunosorbent assay (ELISA). Ab-
sorbance at 405 nm was determined with a microplate
reader.
Viability
Cell viability was assessed by staining cells with Trypan
blue solution (5%) and numbering non-viable (blue) cells
under microscope (× 20) in four 1 × 1mm squares of
one chamber and determining the average number of
cells per square.
Co-immunoprecipitation and GTP-rho, NDR2/GEF-H1 pull-
down assays
Cells were lysed in chilled immunoprecipitation buffer
and the cleared lysate (500 μg) incubated with 3 μg of
the indicated antibody and 30 μL of protein-A agarose
beads (Repligen) in 1 mL of buffer. Beads were resus-
pended in 30 μL of 2X Laemmli buffer and subjected to
Western blotting.
For GTP-pulldown assays, cell lysates were incubated
with beads glutathione-S-transferase (GST)-Rhotekin
Rho binding domain (RBD), GST-NDR1 or GST-NDR2
(Carna Biosciences, Japan), then precipitates analyzed by
Western blotting using anti-RhoB, anti-GEF-H1 or
anti-S885phospho-GEF-H1 antibodies.
Live cell imaging and analysis
Cells were grown on 35-mm coverglass bottom dishes
(MatTek). The microscope was equipped with an open
chamber (Pecon) equilibrated in 5% CO2 and maintained
at 37 °C. Images were taken at 2-min intervals with a ×
20 or × 60 objective using a RTKE camera controlled by
the Micromanager software. Video analysis was per-
formed by ≥ImageJ software.
Statistical analysis
Data are means ± SEM (n ≥ 3). Statistical differences
were determined by one-way analysis of variance
(ANOVA) followed by Dunnett’s Multiple Comparison
Test (GraphPad Software, Inc. USA). Statistical signifi-
cance was set at p ≤ 0.05. Chi2 test was used to test cor-
relation between events. We used kpm.plot.com online
software to compute the mRNA prognostic analyses in
681 Stage I-to-III patients, with gene-expression data
and OS information downloaded from the GEO (Affy-
metrix microarrays only), EGA, and TCGA databases.
Results
Depletion of the NDR1/2 kinases reverts the migratory
and metastatic phenotypes induced by RASSF1A loss in
HBEC
Forty-eight hours after silencing RASSF1A or NDR1/2
in HBEC cells using siRNAs (Additional file 1: Table S2),
we performed wound healing (Fig. 1a) and invasion
(Fig. 1b) assays in the presence of mitomycin C, to in-
hibit the contribution of cell division in wound repair.
The increase of migration and invasion induced by
RASSF1A loss in HBEC-3 cells ([3], Fig. 1a and b) was
inhibited by NDR1/2 depletion (Fig. 1a and b) without
leading to cell death (cytochrome c release: Add-
itional file 2: Figure S1A, cell viability: Additional file 2:
Figure S1B). NDR1/2 silencing also decreased the migra-
tory and invasive properties in RASSF1A-null HBEC as
illustrated for H1299 (Additional file 2: Figure S2A/Fi-
gure S2B), A549 (Additional file 2: Figure S2A/Figure
S2B) and H1650 lung cancer cells (Additional file 2:
Figure S2A/Figure S2B, and Additional file 3: Movie S1/
Additional file 4: Movie S2 for siNeg and siNDR2
respectively) again, without leading to cell death
(Additional file 2: Figure S2C, except for NDR2 silencing
in H1650 cells). To ensure that the observed effects are
only related to the extinction of NDR1 or NDR2 and not
to off-target effects, we have transfected HBEC-3 cells
with siNDR1 and NDR1 plasmid (plsNDR1) or with
siNDR2 and NDR2 plasmid (plsNDR2), to restore a
basal expression of NDR1 or 2 in cells of which en-
dogenous NDR1 or 2 was silenced (Additional file 2:
Figure S3A), before reevaluating 2D (wound healing,
(Additional file 2: Figure S3B)) and 3D migration
(Additional file 2: Figure S3C). With these experiments,
we confirm that siNDR1 or siNDR2 alone actually
decreases 2D migration velocity (Additional file 2:
Figure S3B) or 3D migration (Additional file 2:
Figure S3C), and that these effects are exclusively
due to NDR1 or NDR2 silencing, since cells rescued for
their expression of NDR1 or NDR2 (transfected by
siNDR1 + plasmideNDR1 or siNDR2 + plasmideNDR2),
moved as did control cells (siNeg) (Additional file 2:
Figure S3B and Figure S3C).
We next infected RASSF1A-null A549 or H1299 cells
with lentivirus expressing shRNAs targeting NDR1 or
NDR2 (A549: Fig. 1c, H1299: Additional file 2: Figure S2D).
In SCID−/− Beige mice, tumors formed by shNDR1- or
shNDR2 A549 cells emerged later than tumors formed by
shcontrol-A549 cells and grew more slowly (Fig. 1c).
In H1299 cells, carrying a p53 homozygous deletion
and a RASSF1A-gene methylation [12], NDR1 dele-
tion did not affect xenograft growth compared to
controls (Additional file 2: Figure S2D) while tumors
formed by NDR2-depleted H1299 cells were smaller
in size than controls (Additional file 2: Figure S2D).
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NDR2-depleted cancer cells formed less lung and liver
metastatic foci than sh-control or shNDR1-depleted cells
(A549: Fig. 1d, H1299: Additional file 2: Figure S2E). Im-
munohistochemistry and Western blot analysis con-
firmed that shNDR1 or shNDR2 infected primary
tumors actually exhibited decreased NDR1 or NDR2
expression (A549: Fig. 1c and Additional file 2: Figure S4A,
H1299: Additional file 2: Figure S2D and Additional file 2:
Figure S4B).
Migratory and metastatic phenotypes induced by
RASSF1A loss in HBEC could be thus reverted by
NDR1/2 silencing.
A B
C
D
Fig. 1 NDR depletion abolishes mobility and metastasis properties in HBEC with RASSF1A depletion. HBEC-3 were transfected with non-silencing
siRNA (siNeg), siRASSF1A and/or with siNDR1 or siNDR2. Experiences were performed 48 h after transfection. A549 cells were transfected with
shcontrol, shNDR1 or shNDR2. a Wound healing assay of HBEC-3 cells on collagen IV coating were performed 48 h after transfection. Scale bar
represents 100 μm. b Invasion capacity of HBEC-3 cells on BioCoat Matrigel Invasion Chamber. Relative invasion normalized to that of the cells
transfected with siNeg. Scale bar represents 80 μm. c-d ShNDR1 or shNDR2-infected A549 cells suspension were injected subcutaneously in
SCID−/− Beige mice. c Xenograft tumor size [length (L)/width (l)/thickness (e)]. NDR1 and NDR2 mRNA levels of the injected cells, representative
xenograft and NDR1 or NDR2 expression assayed by immunohistochemistry on xenografts are presented respectively on the left of, on the right
of and below the xenografts growth curves. d Quantification of lung and liver microscopic nodules metastases for A549 cells expressing shNDR1,
shNDR2 or shcontrol. Excised mice lung and liver as histologic photographs of the lung and liver metastases after injection with shNDR1, shNDR2
or shcontrol are presented below the quantification. Error bars indicate the standard error of the mean (SEM) (n ≥ 3). *P < 0.05, **P < 0.01 and
***P < 0.001, using an ANOVA test followed by Dunnett test
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NDR-kinases depletion partly reverts EMT induced by
RASSF1A loss
RASSF1A depletion increased HBEC motility in part by
inducing EMT [3]. We tested whether NDR1/2 silencing
could revert EMT phenotype. NDR1 as NDR2 depletion
abolished mesenchymal marker expression in RASSF1A-
depleted HBEC-3 cells (Fig. 2a, bottom histogram).
NDR2 silencing restored E-Cadherin, but not ZO-1
expression, upon RASSF1A knockdown (Fig. 2a, upper
histogram). The expression of epithelial and mesenchy-
mal markers was also altered by NDR1/2 manipulations
in two other lung cancer cells null for RASSF1A
(H1299: Additional file 2: Figure S5A, A549: Fig. 2b).
NDR1 as NDR2 depletion increased epithelial marker
(Fig. 2b, cf. E-Cadherin and Syndecan-1) and decreased
Vimentin (Fig. 2b) expression in RASSF1A-null A549
cells. Finally, in RASSF1A-null H1299 cells, NDR1 as
NDR2 depletion increased Syndecan-1 (Additional file 2:
Figure S5A) and decreased Vimentin (Additional file 2:
Figure S5A) expression.
In HBEC xenografts, upon NDR2 depletion, E-cadherin
is also report to be slightly increased (A549 xenografts:
A
B
C D
Fig. 2 NDR depletion abolishes EMT induced by RASSF1A silencing in HBEC cells. HBEC-3 (a) or A549 (b) cells were transfected with siNeg,
siRASSF1A and/or with siNDR1 or siNDR2. c-d Xenograft obtained from shcontrol, shNDR1 or NDR2 A549 cells. Quantification of E-Cadherin,
syndecan-1, ZO-1, vimentin and/or N-cadherin by western blot (a, c), Immunofluorescence (b) or immunohistochemistry (d). Error bars indicate
the SEM (n ≥ 3). *P < 0.05, **P < 0.01 and ***P < 0.001, using an ANOVA test followed by Dunnett’s test
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Fig. 2c, H1299 xenografts: Additional file 2: Figure S5B)
and restored at the membrane (A549 xenografts: Fig. 2d,
H1299 xenografts: Additional file 2: Figure S5C). Con-
versely, vimentin expression is decreased by NDR1 or
NDR2 knockdown in A549 (Fig. 2c and d) or H1299
(Additional file 2: Figure S5B and Additional file 2:
Figure S5C) xenografts when compared to shControl
xenografts.
NDR1/2 knockdown could thus partly prevent EMT
upon RASSF1A silencing in HBEC.
NDR-kinases depletion impairs YAP activation in
RASSF1A-depleted HBEC
Increased migration of RASSF1A-depleted HBEC-3 cells
being YAP-dependent, ([3], Fig. 3a), we wondered whether
NDR1/2 depletion could revert YAP activity upon
RASSF1A loss. We found that NDR1 or NDR2 deple-
tion did prevent YAP nuclear localization in
RASSF1A-depleted (HBEC-3, Fig. 3a) or -null (A549
and H1650, Additional file 2: Figure S6A) cells. NDR1 or
NDR2 silencing also diminished CTGF and ANKRD1
mRNA (Fig. 3 Bi-ii and Additional file 2: Figure S6Bi-ii),
two transcriptional targets of YAP [13]. Nuclear YAP in-
tensity in RASSF1A-null xenografts depleted for NDR1 or
NDR2 was reduced compared to shControl xenografts
(H1299: Additional file 2: Figure S6C, A549: Fig. 3c),
and led to partly YAP inactivation as shown by the
diminished CTGF and ANKRD1 mRNA in A549 xe-
nografts depleted for NDR1 or NDR2 compared to
shControl (Fig. 3 Di-ii).
Thus, in RASSF1A-depleted HBEC, NDR1/2 could get
activated and lead to the YAP activation with a subse-
quent increase of motility.
NDR2 contributes to the regulation of RhoB activity
The RhoB GTPase playing an important role in the migra-
tion downstream of RASSF1A loss [3], we tested whether
NDR1/2 contribute to the RhoB regulation upon RASSF1A
loss. By forcing re-expression of RASSF1A in H1299 cells,
we observed an increase in the activated (GTP-bound)
form of RhoB (Fig. 4a). Depletion of NDR1/2 increased the
levels of the active GTP-bound RhoB form, while the res-
toration NDR1 or NDR2 expression decreased the
GTP-bound RhoB (Fig. 4a). We further confirmed that de-
pletion of RASSF1A decreased the levels of active form
RhoB ([3], Additional file 2: Figure S7A) and reported that
RhoB activity was restored in RASSF1A-depleted HBEC-3
cells upon NDR2 silencing (Additional file 2: Figure S7A)
but not upon NDR1 silencing (Additional file 2:
Figure S7A). NDR2 depletion can thus restore RhoB
activation in RASSF1A null HBECs.
NDR2 interacts with GEF-H1 resulting in S885-GEF-H1
hyper-phosphorylation and subsequent GEF-H1
inactivation
Considering that RhoB is regulated by NDR2 (Fig. 4a
and Additional file 2: Figure S7A) and GEF-H1 [3, 14],
we tested whether NDR1/2 are involved in GEF-H1
regulation. In line with our previous finding [3], we
showed that NDR2 but not NDR1 silencing decreased
GEF-H1 phosphorylation upon RASSF1A loss (Fig. 4b).
The specificity of the phospho-Ser885-GEF-H1 antibody
was further supported by λ-phosphatase pretreatment of
the protein extract, which actually abolished the phos-
phorylation band revealed in GEF-H1 (Fig. 4b). NDR2
could thus regulate the GEF-H1 activity and then, the
regulation of RhoB by GEF-H1.
Observing a stronger GEF-H1/NDR2 co-staining in
RASSF1A-depleted HBEC-3 cells than in controls, as well
as a co-staining in RASSF1A-depleted HBEC-3 cells ex-
pressing an exogenous wild-type form of GEF-H1 (Fig. 5a),
we tested whether GEF-H1 can interact with NDR2. We
failed to detect an NDR2/GEFH1 interaction by
co-immunoprecipitation with available antibodies (not
shown), and tested whether this interaction could be fa-
vored by another partner. Indeed, syndecan-1 (SDC1), was
previously shown by others to interact with GEF-H1 [15]
and influence Rho activation [16], while we also reported
SDC1 decreased upon RASSF1A loss [3]. Actually, in
SDC1 immunoprecipitates from HBEC-3 cells extracts, we
were able to detect both NDR2 and GEFH1, while none of
them was detected upon SDC-1 silencing (Additional file 2:
Figure S7B). Thus, an in vivo interaction between NDR2
and GEF-H1 does occur needing SDC1 mediation.
Using recombinant GST-NDR2, we also pulled-down
endogenous GEF-H1 from HBEC-3 cell extracts (Fig. 4c,
GST-assay while, endogenous GEF-H1 was not
pull-down with GST-NDR1 or upon GEF-H1 knock-
down (Fig. 4c). We expressed RNAi-resistant GEF-H1
versions in GEF-H1-depleted cells, and consequently
tested their binding to GST-NDR2 (Fig. 4c). We com-
pared wild-type GEF-H1 (pls WT-GEF-H1) with two
phosphor-acceptor mutants termed GEF-H1 S265A and
GEF-H1 S885A (Additional file 2: Figure S8) since S265
is included in the putative NDR phosphorylation motif
HXRXXS/T [17] and S885 contributes to GEF-H1 activity
[18]. We detected a strong Ser885 phosphorylation of
GEF-H1 in total protein cell extract from
WT-GEF-H1-transfected HBEC-3 cells, but not in extracts
from GEF-H1-S885A or GEF-H1-S265A-transfected
HBEC-3 cells (Fig. 4c, input, top lane). Finally, exogenous
GST-NDR2 kinase induced strong GEF-H1 Ser885 phos-
phorylation on exogenously expressed wild-type GEFH-1
retained on beads, while NDR2 beads only retained a low
amount of phosphoSer885 GEF-H1 on exogenously
expressed S885A, and more interestingly S265A GEF-H1
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mutants (Fig. 4c, GST assay). All these data suggest a link
between the phosphorylations of Ser265-GEF-H1 and
Ser885-GEF-H1.
RASSF1A depletion delays abscission and alters
cytokinesis in bronchial cells lines
RASSF1A [19, 20], NDR1/2 kinases [21], GEF-H1 [10, 22]
and YAP [23] controlled mitosis, but whether these pro-
teins act together is not understood. We first characterized
the mitotic phenotypes associated with RASSF1A loss in
HBECs. We detected no alteration in the equatorial plan
definition or the equatorial structure processing in
RASSF1A-depleted HBEC, as evidenced by normal staining
of the main protagonists involved in such steps: MKLP1
(Additional file 2: Figure S9A), PRC1 (Additional file 2:
Figure S9B) RhoA (Additional file 2: Figure S9C), Rac1
(Additional file 2: Figure S9D), or Ect2 (Additional file 2:
Figure S9E). Conversely, RASSF1A inactivation increased
A B
C D
Fig. 3 NDR depletion abolishes YAP activation induced by RASSF1A silencing in HBEC cells. a-b HBEC-3 cells were transfected with siNeg,
siRASSF1A and/or with siNDR1 or siNDR2. c-d Xenograft obtained after subcutaneous injection of shcontrol, shNDR1 or NDR2 H1299 cells. Nuclear
YAP quantification by immunofluorescence (a) or by immunohistochemistry (c). b, d Quantification of CTGF (Bi, Di) & ANKRD1 (Bii, Dii) mRNA
using actin as an internal control in HBEC-3 cells. Error bars indicate the SEM (n≥ 3). *P < 0.05, **P < 0.01 and ***P < 0.001, using an ANOVA test
followed by Dunnett’s test
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A
B
C
Fig. 4 NDR2 interacts and phosphorylates GEF-H1 in HBEC. HBEC-3 or H1299 cells were transfected with siNeg and/or siRASSF1A, siNDR1, siNDR2,
siGEF-H1, pcDNA3-NDR1, pcDNA3-NDR2 or pcB6-GEF-H1. a GST-RBD pull-down assay in H1299 cells. b Ser885 phosphorylation from GEF-H1 assayed
by western blot following λ-phosphatase pre-treatment of the total protein extract or not and normalized with total GEF-H1 expression in HBEC-3 cells.
c GST-NDR1 or -NDR2 pull-down assay using siRNA & GEF-H1 plasmid as controls. NDR2 phosphorylation on Ser265-GEFGH1 link with phosphorylation
on Ser-885-GEF-H1A was assayed. NDR2 activity on HBEC-3 cells extracts previously transfected with pcB6-GEF-H1 wild type, mutated on Ser265
(S265A), or on Ser885 (S885A) was assayed by quantifying ser885-GEF-H1 phosphorylation status by western blot following normalization by total GEF-
H1 expression. Error bars indicate the SEM (n≥ 3). *P < 0.05, **P < 0.01 and ***P < 0.001, using an ANOVA test followed by Dunnett’s test
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chromosomes misalignment (Additional file 2: Figure S10A)
and lagging (Additional file 2: Figure S10B) in HBEC-3 as in
HBEC-3-RasV12 cells (Additional file 2: Figure S10C).
RASSF1A inactivation also increased midbody persistence
in HBEC-3 (Fig. 6a) as in HBEC-3-RasV12 cells (Additional
file 2: Figure S10D) as evidenced by α-tubulin and Aurora B
co-staining [24] (Fig. 6a, Additional file 2: Figure S10D) and
by the modification of expression of Anillin (Additional file 2:
Figure S10F), Aurora B (Additional file 2: Figure S10G) and
Citron kinase (Additional file 2: Figure S10H). RASSF1A
A
B
Fig. 5 NDR2 and GEF-H1 are co-stained in HBEC-3 cells during both interphase and cell division. HBEC-3 cells were transfected with siNeg or
siRASSF1A. a GEF-H1 and NDR2 co-staining assayed by immunofluorescence in HBEC-3 cells during interphase. b Representative images are
shown for NDR2 and GEF-H1 during mitosis. Localization was identified by immunofluorescence and confocal microscopy. Costaining was
evaluated by ImageJ software. HBEC-3 cells were also stained with DAPI for DNA and PSer885GEF-H1 during mitosis. Error bars indicate the SEM
(n ≥ 3). *P < 0.05, **P < 0.01 and ***P < 0.001, using an ANOVA test followed by Dunnett’s test
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loss delayed the transition from the onset of furrowing to
completion of abscission (Additional file 2: Figure S10I,
Additional file 6: Movie S4/ Additional file 7: Movie S5) and
increased the number of cells with failing mitosis evidenced
by increased numbers of i) round cells never entering into
mitosis (Fig. 6b, Additional file 8: MovieS6), ii) cells never
initiating cytokinesis (Fig. 6b, Additional file 9: MovieS7), or
iii) cells never terminating abscission and exhibiting broad
cytoplasmic bridges interconnecting daughter cells (Fig. 6b,
Additional file 10: MovieS8) and iv) of bi- or
multi-nucleated HBEC-3 (Additional file 2: Figure S10 J) or
HBEC-3-RasV12 cells (Additional file 2: Figure S10Q), with
independent initiation of mitosis for nuclei from a same
HBEC-3 cell (shown by confocal acquisition of siRASSF1A
transfected cells, Additional file 5: MovieS3). Supporting the
midbody abscission defect we suspected, we reported accu-
mulation of Spastin and Fidgetin, two enzymes involved in
midbody cut (Additional file 2: Figure S11A), and alterations
in the content of Rab11 (increased) and Syntaxin16 (de-
creased) (Additional file 2: Figure S11B), two crucial proteins
for intracellular traffic and mitosis [25, 26]. Thereby,
RASSF1A depletion affected cytokinesis beyond the only
step of the midbody formation described by others [20].
Cytokinesis disorders induced by RASSF1A depletion are
YAP-dependent
We tested the contribution of YAP on the cytokinesis phe-
notypes associated with RASSF1A loss. YAP depletion
A B
C
α
α
Fig. 6 RASSF1A depletion induces YAP-dependent cytokinesis defect. HBEC-3 cells were transfected with si-RASSF1A, siYAP and/or si-Neg. Cells
were stained with anti-RASSF1A, anti-tubulin and/or anti-AuroraB antibodies and DAPI. Persistent midbody was quantified (a) as the number of
cells failing to divide following cytokinesis defect by scoring > 100 cells, imaged at 2 min intervals when rounded up (b). c Percentage of HBEC-3
cells multinucleated and/or with persistent midbody evaluated following RASSF1A and YAP silencing and immunostaining of the alpha-tubulin
with DAPI for the nucleus. a, c Scale bar represents 50 μm. Error bars indicate the SEM (n ≥ 3). *P < 0.05, **P < 0.01 and ***P < 0.001, using an
ANOVA test followed by Dunnett’s test. b Correlation between RASSF1A presence and events was test using a Chi2 test
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alone did no affect the number of multinucleated cells or
persistent midbodies compared to controls (Fig. 6c) but
significantly decreased the number of multinucleated cells
and persistent midbody in RASSF1A-depleted HBEC-3
(Fig. 6c). Thus, the cytokinesis disorders induced by
RASSF1A loss could be dependent of YAP in HEC.
GEF-H1 and NDR2 co-staining is divergent upon RASSF1A
loss during mitosis
We wondered whether NDR2-associated GEF-H1 inacti-
vation in RASSF1A-depleted cells could be responsible
for the cytokinesis defects observed upon RASSF1A loss.
In wild-type HBEC-3 cells, GEF-H1 and NDR2
co-staining was mainly observed at the early prophase,
during the establishment of the equatorial plane, at the
end of telophase and during abscission (at the cleavage
point) (Fig. 5b) suggesting an involvement of NDR2 in
the regulation of GEF-H1 activity during these mitotic
steps. In RASSF1A-depleted HBEC-3 cells, NDR2/
GEF-H1 co-staining features were considerably different
at (Fig. 5b): i) the early prophase (the sub-cortical
co-staining signal observed in control cells were lower) ii)
the equatorial plane step (co-staining was fainter than in
controls), iii) the contractile ring assembly (co-staining
was stronger in RASSF1A-depleted cells) and iv) the ab-
scission step (with a decreased signal at the midbody).
NDR2 and GEF-H1 do not localize identically in
RASSF1A-depleted or RASSF1A wild type HBEC, sug-
gesting that mitosis alteration in RASSF1A depleted-cells
could be transmitted by altered NDR2 and GEF-H1
localization/activation.
GEF-H1 depletion mimics cytokinesis defects induced by
RASSF1A loss
Testing whether the inactivation of GEF-H1 could explain
the cytokinesis disorders observed upon RASSF1A loss,
we depleted GEF-H1 in HBEC-3 cells (Additional file 2:
Figure S12A). Single depletion of RASSF1A elevated
the number of multinucleated cells compared to con-
trols (Additional file 2: Figure S12A) while GEF-H1
silencing increased the proportion of binucleated cells
(Additional file 2: Figure S12B) without affecting the
number of persistent midbodies (Additional file 2:
Figure S12C). Co-depletion of RASSF1A and GEF-H1
did not increase the number of multinucleated cells
(Additional file 2: Figure S12A) but increased the pro-
portion of attached daughter cells (Additional file 2:
Figure S12B). GEF-H1 inactivation could thus lead to
cytokinesis disorders in HBEC.
GEF-H1 overexpression, or NDR2 knockdown restores
cytokinesis in RASSF1A-depleted cells
To further examine the mitotic link between GEF-H1 and
NDR2 upon RASSF1A loss, we overexpressed wild-type
GEF-H1 or silenced NDR2 in RASSF1A-depleted HBEC-3
cells. GEF-H1 overexpression (Fig. 7a) restored cytokinesis
in RASSF1A-depleted cells as judged by the number of
bi-nucleated cells (Fig. 7a) or cells with persistent midbo-
dies (Fig. 7b) compared with controls cells. Similarly,
NDR1 or NDR2 depletion decreased the rate of multinu-
cleated cells upon RASSF1A loss (Fig. 7c), however only
NDR2 silencing suppressed the formation of persistent
midbodies (Fig. 7 c). Alike, NDR2, but not NDR1 deple-
tion in RASSF1A-null H1299 cells decreased the number
of multinucleated cells and persistent midbody (Add-
itional file 2: Figure S12C). Thus, both GEF-H1 and
NDR2 could function as mediators of cytokinesis failures
upon RASSF1A loss.
Low RASSF1A, low RhoB-GEF-H1 or high NDR2 kinase
mRNA cell content predicted worse overall survival of
lung cancer patients
Consistently with a molecular machinery where
RASSF1A, NDR2, GEF-H1 and RhoB work in concert,
analysis of survival of resected early lung cancer patients
from The Cancer Genome Atlas cohort, showed that
low mRNA expression of RASSF1A (Additional file 2:
Figure S13A), RhoB (Additional file 2: Figure S13B), and
GEF-H1 (Additional file 2: Figure S13C) predict worse
overall survival in NSCLC patients as high expression of
NDR2 mRNA (Additional file 2: Figure S13C).
Discussion
We recently reported that RASSF1A acts both as a
tumor and metastasis gene suppressor in patients with
early stage non-small cell lung cancer (NSCLC) [1, 3],
RASSF1A both restricting activation of YAP, one of the
terminal target of the Hippo pathway, and stimulating
activation of RhoB, a small anti-migratory GTPase pro-
tein, via GEF-H1, its GDP/GTP exchange factor [3].
Here, we report that the NDR2 kinase is required for
YAP activation and RhoB/GEF-H1 inactivation in
RASSF1A-depleted human bronchial cells, consequently
supporting the pro-invasive and cytokinesis disorders
upon RASSF1A loss.
Our report of a pro-oncogenic role for a NDR kinase,
in a context where RASSF1A is lost, is rather unex-
pected, taking into account for a previously reported role
as a YAP kinase, contributing to YAP cytoplasmic se-
questration, but in line with recent studies in
Ras-transformed human cells [27, 28]. Indeed, in Ras
transformed HEK-HT cells, NDR1 knockdown was
shown to impair anchorage-independent soft agar cell
growth and in vivo xenograft growth [27]. In addition,
that NDR1/2 kinases are involved in the control of these
movements is reminiscent of a comparable function
assigned to their close homologs, the LATS1/2 kinases
[29, 30]. Mechanistically, such action could involve
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NDR2 regulation of β1 integrin [31], which is required
for invasive cell capabilities [32] and known to regulate
nuclear location of YAP1 [33]. In our model, we previously
reported a nuclear increase of YAP in RASSF1A-depleted
cells, while we show here, that NDR2 activity is required
for such YAP activation (Fig. 3, Additional file 2: Figure S6).
However, to date, there is no report of a link between
the NDR kinases activities and extracellular matrix re-
modeling, so an alternative hypothesis explaining how
NDR kinase influences cell motility could involve its
control on cell adhesion and/or cytoskeleton remodeling,
NDR kinase pathway being previously reported to coord-
inate cell cycle dependent actin rearrangements [34].
That NDR kinases control cell motility is also consist-
ent with the contribution of NDR kinases to EMT/MET
processes (Fig. 2, Additional file 2: Figure S5), previously
suggested by the report of NDR kinases influence on cell
differentiation during organogenesis [35] and their abil-
ity to inhibit TGFβ [36], a cytokine leading squamous
differentiation of non-transformed HBEC [37]. In our
model, the control of NDR on the mesenchymal pheno-
type appears related to the control that NDR kinases
exert on YAP. Indeed, we had reported that the EMT in-
duced by RASSF1A silencing in HBEC was correlated
with the abnormal activation of YAP in these cells [3].
Here, we show that in the absence of NDR, the EMT of
RASSF1A-depleted HBEC is partially reverted, which is
correlated with YAP inactivation in HBEC lacking both
RASSF1A and NDR kinases.
We also report here, that NDR loss can revert migratory
and cytokinetic abnormalities of RASSF1A-depleted cells
by preventing YAP activation (Fig. 3, Additional file 2:
Figure S6). NDR kinases may therefore up- or down-regu-
late YAP activity, depending on the cellular context, which
α
α
α
Fig. 7 GEF-H1 overexpression as NDR depletion restores cytokinesis of RASSF1A depleted human bronchial cells. HBEC-3 (a-c) were transfected
with siNeg, siRASSF1A and/or with siNDR1, siNDR2 or pcB6-GEF-H1 (a). The number of binucleate (a, c) and interconnected cells (b, c) were
counted after alpha-tubulin and DAPI staining from cells over-expressing or not GEF-H1 (a) or silenced for NDR kinases (c) in HBEC-3. These
numbers are expressed as a percentage in control and siRNA-transfected cells. Error bars indicate the SEM (n ≥ 3). *P < 0.05, **P < 0.01 and
***P < 0.001, using an ANOVA test followed by Dunnett’s test
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could explain these kinases may behave as oncogenes or
tumor suppressor genes [7]. YAP is indeed able to exert
pro-oncogenic action by reprogramming cells behavior
[38], or anti-oncogenic functions, by inhibiting tumors oc-
currence in mice [39]. An oncogenic function of NDR2 is
supported by reports, showing that NDR2 supports MYC
protein stability [40] and thus contributes to oncogenic
Ras transformation [28]. In addition, high level of NDR1
[41] or NDR2 [42] mRNAs were found in non-small cell
lung cancer. Our work originally shows that a NDR kinase
contributes to oncogenic functions in a lung cancer model
involving cancer cells carrying Ras (A549 cells with Ras
G12S) or p53 mutations (p53-deleted H1299 cells).
NDR kinases leading to the nuclear exclusion of YAP
[7], it was surprising here that the depletion of NDR
kinases decreased YAP nuclear levels and activity in
cells lacking of RASSF1A. We suggest that in
RASSF1A-depleted HBECs, the nuclear localization of
YAP is possibly not linked to the canonical Hippo
pathway, but rather connected to the RhoB inactivation
[3], such being the situation when mechano-transduction
mobilizes YAP1 [43]. Actually, we found that NDR deple-
tion reverts the inhibition of GEF-H1/RhoB in
RASSF1A-depleted cells (Fig. 4, Additional file 2: Figure
S7, Fig. 5). This finding is fully consistent with our previ-
ous work demonstrating that the nuclear localization of
YAP is caused by the inactivation of RhoB upon loss of
RASSF1A [3]. Our data showing that NDR kinases are in-
deed at the origin of the inactivation of RhoB and activa-
tion of YAP, also suggest that NDR could be involved in
the mechano-transduction regulation.
The NDR2 kinase could therefore be one of the kinases
responsible for the inactivation of GEF-H1, and the subse-
quent RhoB inactivation in RASSF1A depleted cells. In sup-
port of this hypothesis we observed that (1) NDR2
depletion decreased Ser885-GEF-H1 phosphorylation (i.e.
NDR2 depletion increased the levels of inactive GEF-H1) in
RASSF1A-depleted cells (Fig. 4b), (2) NDR2 depletion in-
creased the levels of GTP-bound, hence activated RhoB
(Fig. 4a, Additional file 2: Figure S7A), (3) NDR2 displayed
increased co-staining with phosphorylated Ser885-GEF-H1
in RASSF1A depleted-HBEC (Fig. 5a), (4) using exogenous
proteins, NDR2 can interact with GEF-H1 in a fashion
dependent on Ser265 and Ser885 (Fig. 4c), and (5) using
co-immunoprecipitation of SDC1-containing complexes,
we were able to show an in vivo association of GEF-H1 and
NDR2 (Additional file 2: Figure S7B). Collectively, these
findings actually suggest that NDR2 can directly interact
with, and inhibit GEF-H1. Possibly, NDR2-induced
GEF-H1 phosphorylation on Ser265, might in turn lead to
increased phosphorylation of GEF-H1 Ser885 by another
kinase, consequently resulting in the loss of GEF-H1 activ-
ity (Fig. 4, Additional file 2: Figure S7, Fig. 5). However, this
model remains speculative at the moment, requiring inten-
sive structure focused studies in the future. Nevertheless,
our hypothesis is further supported by recent studies show-
ing that GEF-H1 can actually be phosphorylated on Ser265
[44] and that GEFs are frequently inactivated by successive
phosphorylation events [45].
The link we established between the RhoB/GEF-H1/
NDR2/YAP and RASSF1A signaling in the context of EMT
and migration led us to explore another process
Fig. 8 A proposal model for RASSF1A regulation of the NDR2/GEFH-1/RhoB/YAP axis
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deregulated in RASSF1A depleted HBEC, namely mitosis/
cytokinesis. We provide evidence that the deregulation of
one member of this interactome is sufficient to disrupt
cytokinesis in RASSF1A-knockdown cells, a feature consist-
ent with i) the RASSF1A localization with the microtubules
at contractile ring and midbody [46, 47], ii) the YAP
localization to the midbody and spindle [23], iii) the
GEF-H1 localization at the tips of cortical microtubules
and the midbody [10], iv) the lower co-staining of GEF-H1
and NDR2 at early prophase, at equatorial plane positioning
and during midbody formation, when compared to
RASSF1A wild-type cells (Fig. 6). Such result sustains the
role of RASSF1A/NDR2/GEF-H1/RhoB axis in cytokinesis
in addition to its role in cell migration that we also support
here.
Conclusion
We propose the following model: in healthy bronchial
lung cells, RASSF1A inhibits NDR2, leaving rhoGEF-H1
active and leading to RhoB activation, which can exert in
turn its anti-metastatic activity (Fig. 8). Thus, NDR2 kin-
ase appears to be a potential therapeutic target in patients
with lung cancer and loss of RASSF1A expression, who
account for more than 30% of all lung cancer patients.
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